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Abstract
Background: Only about half the studies that have collected information on the relevance of women’s height and body
mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we
bring together the worldwide evidence, published and unpublished, and describe these relationships.
Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer
from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer
were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body
mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm
increase in height was 1.07 (95% confidence interval [CI], 1.05–1.09; p,0.001); this relationship did not vary significantly by
women’s age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having
had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of
menopausal hormone therapy. For body mass index, there was significant heterogeneity (p,0.001) in the findings between
ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk
for ovarian cancer per 5 kg/m2 increase in body mass index was 1.10 (95% CI, 1.07–1.13; p,0.001) in never-users and 0.95
(95% CI, 0.92–0.99; p = 0.02) in ever-users of hormone therapy.
Conclusions: Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index.
In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the
disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated
with a 3% increase in ovarian cancer incidence per decade.
Please see later in the article for the Editors’ Summary.
Citation: Collaborative Group on Epidemiological Studies of Ovarian Cancer (2012) Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including
25,157 Women with Ovarian Cancer from 47 Epidemiological Studies. PLoS Med 9(4): e1001200. doi:10.1371/journal.pmed.1001200
Academic Editor: Eduardo L. Franco, McGill University, Canada
Received July 15, 2011; Accepted February 24, 2012; Published April 3, 2012
Copyright:  2012 Collaborative Group on Epidemiological Studies of Ovarian Cancer. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are
credited.
Funding: Funding for this collaborative reanalyis of original data was provided by Cancer Research UK. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: CI, confidence interval; g-s CI, group-specific confidence interval
* E-mail: collaborations@ceu.ox.ac.uk
PLoS Medicine | www.plosmedicine.org 1 April 2012 | Volume 9 | Issue 4 | e1001200
Introduction
About 50 epidemiological studies of ovarian cancer have
collected information on the relevance of women’s adult height
and weight to their subsequent risk of ovarian cancer [1–52]. Only
about half these studies have published their results on the
association between body size and ovarian cancer risk, and the
findings are inconsistent [22,24,25,29,33,37–41,44–52]. An inter-
national collaboration was set up to bring together, re-analyse, and
publish the available epidemiological evidence on the association
between hormonal, anthropometric, and other factors and ovarian
cancer risk [53]. This report describes the relationship between
ovarian cancer risk and adult height, weight, and body mass index,
and examines the consistency of the findings across study designs,
across subgroups of women, and by tumour histology. Data from
studies that had and had not published on the association with
body size are included here, as this helps avoid unduly selective
emphasis on particular studies, or just on published results.
Methods
Identification of Studies and Collection of Data
Our collaboration began in 1998, and since then potentially
eligible epidemiological studies have been sought regularly, by
searches of review articles and through computer-aided literature
searches in MEDLINE, EMBASE, and PubMed using combina-
tions of the search terms ‘‘ovarian cancer’’, ‘‘ovary cancer’’,
‘‘height’’, ‘‘body mass index’’, ‘‘body size’’, ‘‘anthropometr*’’. To
be eligible for these analyses, studies needed to have collected
individual data on women’s reproductive history, use of hormonal
therapies, height, weight, and/or body mass index, studied at least
200 women with ovarian cancer, and published their findings
before 1 January 2009. (Before 2006, studies with fewer than 200
cases of ovarian cancer had been eligible, and so there are fewer
cases in some studies.) Studies that had collected relevant data but
had not published on ovarian cancer and body size were sought by
correspondence with colleagues, by discussions at collaborators
meetings (in 2000, 2005, and 2011), and by electronic searches
using the additional terms ‘‘cohort’’, ‘‘prospective’’, ‘‘women’’, and
‘‘cancer risk’’.
We identified 51 eligible studies and invited principal
investigators from each study to participate in the collaboration.
Investigators from just one eligible study [49] did not respond to
any of our enquiries, and investigators from another study [48]
wrote to say that they were unable to participate. Two other
studies [50,51] have contributed to the collaboration, but their
data were not available for these analyses. Thus, data from 47 of
the 51 eligible studies identified are analysed here. The
implications of this are discussed later.
‘‘Cases’’ are women with malignant epithelial or non-epithelial
ovarian cancer and ‘‘controls’’ are women without ovarian cancer
who had not undergone bilateral oophorectomy. Information
sought from principal investigators about every control and about
every case included their age, ethnic group, education, height,
weight and/or body mass index, age at menarche, reproductive
history, use of hormonal contraceptives, use of menopausal
hormonal therapy, hysterectomy, family history of ovarian or
breast cancer, and consumption of alcohol and tobacco. The
information sought on these factors was for the time preceding the
onset of disease for cases and for an equivalent time for controls.
So that similar analytical methods could be used across studies,
cohort studies were incorporated using a nested case–control
design, in which up to four controls were selected at random and
matched at follow-up by age of the case at entry into the cohort,
age at cancer diagnosis, and, where appropriate, broad geograph-
ical region. In one cohort study ‘‘cases’’ were women with fatal
ovarian cancer [25], whereas in the other studies ‘‘cases’’ were
women with incident disease.
Principal investigators of 47 epidemiological studies included in
the analyses [1–47] provided individual information on adult
height, weight, and/or body mass index for cases and controls
(Table 1). Body mass index was calculated as weight (in kilograms)
divided by height (in metres) squared. In one case–control study
[1], information was available for height but not for weight or
body mass index, and in seven small case–control studies [2–
5,8,9,12], information for body mass index, but not for weight or
height, was available (these seven studies had been conducted
more than 30 y ago, and original data on weight and height could
no longer be retrieved). Information provided by principal
investigators on a woman’s adult weight and height before the
onset of disease was used in these analyses. If more than one value
for either variable was provided for a particular study, the values
used in the analyses were those that best represented the woman’s
height and weight at that time. For retrospective case–control
studies, this was usually women’s height and weight some 1–5 y
before the diagnosis of ovarian cancer, and at an equivalent time
for controls. For prospective studies, principal investigators
generally provided information on women’s height and weight
recorded at the time they were recruited into the cohort. A small
number of women in some of the cohorts may have already lost
weight because of an as-yet-undiagnosed ovarian cancer, and so
sensitivity analyses were done excluding the first 4 y of follow-up in
the prospective studies. All data contributed by principal
investigators were checked and collated centrally so that analyses
could use definitions as similar as possible across studies. Apparent
inconsistencies in the data were rectified, where possible, by
correspondence with the investigators. After the records had been
checked and corrected, investigators were sent summary tables
and listings of the variables to be used in analyses for final
confirmation.
Information on the histological classification of the ovarian
cancers was provided by principal investigators of all but seven
[5,6,9,14,17,25,36] of the 47 participating studies and was used to
categorize tumours centrally, based on the classification system of
the International Classification of Diseases for Oncology [54]. Tumours
were subdivided as epithelial or non-epithelial, and the epithelial
tumours were further classified as clear cell, endometrioid,
mucinous, serous, mixed, or other. Wherever possible the
epithelial tumours were further subdivided into those that were
of borderline malignancy or fully malignant.
Statistical Analysis and Presentation of Results
The analytical methods were similar to those used previously
[53]. Data from different studies were combined by means of the
Mantel-Haenszel stratification technique, subdividing data into
fine strata, each with a separate estimate of standard ‘‘observed
minus expected’’ (O2E) numbers of women with ovarian cancer,
together with their variances and covariances [55,56]. Use of these
simple stratified O2E values has the advantage of avoiding
assumptions about the precise forms of any relations in the data.
The stratified O2E values, together with their variances, were
summed to yield both odds ratios (subsequently referred to as
relative risks) and associated p-values. When only two groups were
compared, relative risk estimates were obtained from the O2E
value and its variance (var[O2E]) by the one-step method [55,56],
as were their standard errors and confidence intervals (CIs). (The
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Mean Height (cm)/Mean Body
Mass Index (kg/m2) (Controls)
Prospective studies (n = 17)
Oxford/FPA (UK) [17] 49/196 1988 1937 48.1 161.5/22.9
BCDDP (US) [38] 353/1,381 1989 1923 65.3 162.0/25.3
Nurses’ Health Study (US) [46] 677/2,710 1991 1930 58.7 163.7/25.3
Iowa Women’s Health [29] 179/716 1991 1924 68.0 162.4/23.8
Radiation technologists (US) [36] 44/176 1992 1945 47.5 164.5/23.6
Netherlands Cohort (Netherlands) [28] 248/1,739 1992 1923 67.8 165.2/25.1
CNBSS (Canada) [43] 481/1,922 1993 1932 59.1 161.7/25.1
Norwegian Counties [31] 130/520 1993 1937 55.1 162.8/25.8
CPS-II Mortality (US) [25] 2,697/1,1367 1994 1923 70.3 162.9/24.8
Swedish mammography [45] 289/1,143 1996 1931 64.1 163.9/25.2
CPS-II Nutrition (US) [39] 355/1,419 1997 1929 67.8 163.8/25.6
WLH (Norway/Sweden) [32] 105/417 1998 1947 48.7 165.9/23.0
NIH-AARP (US) [44] 751/3,009 1999 1932 65.9 163.1/26.7
EPIC (eight European countries) [47] 444/1,788 2000 1935 63.7 161.3/25.6
NOWAC (Norway) [30] 102/414 2000 1940 59.8 164.8/25.0
PLCO (US) [42] 201/805 2001 1933 68.1 163.1/26.9
Million Women Study (UK) [40] 3,753/15,009 2002 1941 61.0 162.0/25.7
All prospective studies 10,858/44,731 1999 1934 64.1 162.7/25.3
Case–control studies with population
controls (n = 17)
Casagrande/Pike (US) [2] 150/150 1974 1932 40.2 NA/22.9
Weiss (US) [11] 298/1,135 1977 1921 55.1 162.2/23.3
CASH (US) [7] 575/4,238 1981 1937 41.9 164.123.0
Whittemore (US) [9] 232/679 1984 1933 50.5 NA/24.0
Shu/Brinton (China) [13] 228/229 1985 1933 48.4 158.5/22.1
Western New York (US) [27] 122/692 1988 1930 58.4 162.9/25.6
Risch (Canada) [15] 450/564 1991 1934 56.7 162.9/24.5
Green/Purdie (Australia) [22] 784/853 1992 1935 55.1 162.0/24.2
Mosgaard (Denmark) [18] 905/1,093 1992 1943 45.9 166.5/23.7
Cramer (US) [24] 563/525 1993 1942 51.1 162.9/25.3
Riman (Sweden) [33] 807/3,875 1994 1932 61.5 163.8/25.3
German OCS [26] 281/531 1995 1937 55.2 163.9/22.1
Pike/Wu (US) [35] 477/660 1995 1939 55.5 163.6/23.4
Goodman/Wu (US) [23] 719/892 1996 1942 55.0 159.0/24.5
NISOC study (Israel) [21] 1,237/2,103 1996 1939 56.0 161.0/25.0
OVCARE (US) [41] 376/1,637 1996 1950 45.7 165.0/24.9
SHARE (US) [37] 767/1,364 1996 1943 51.6 162.5/25.9
All with population controls 8,971/21,220 1994 1939 52.7 163.2/24.3
Case–control studies with hospital
controls (n = 13)
Byers (US) [5] 163/753 1960 1908 52.3 NA/26.4
Newhouse (UK) [1] 280/582 1973 1918 54.1 160.7/NA
McGowan (US) [3] 182/192 1975 1923 50.4 NA//23.3
Paffenbarger (US) [8] 110/480 1975 1917 55.6 NA/24.1
Hildreth/Kelsey (US) [4] 62/1,047 1978 1918 60.1 NA/24.9
Hartge (US) [12] 293/333 1979 1924 54.3 NA/23.2
Booth (UK) [10] 286/489 1980 1927 50.9 162.8/24.1
Rosenberg (US) [16] 952/3,808 1983 1935 49.5 162.8/26.6
Negri/Franceschi(Italy) [14] 957/2,478 1986 1932 53.1 160.9/23.8
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exact formula was as follows: log relative risk = [O2E]/var[O2E]).
When more than two groups were compared, variances were
estimated for every group, by treating the relative risks as floating
absolute risks [57]. This method does not alter relative risk
estimates, but reduces the variances attributed to them (except for
the baseline group, where the relative risk is defined as 1.0) and
allows the relative risk estimates to be treated as approximately
independent in tests of heterogeneity and trend. The group-
specific variances were used to calculate group-specific CIs (g-s
CIs). Use of this method enables valid comparisons between any
two groups, even if neither is the baseline group. Any comparison
between two relative risks must, therefore, take the variation in
each group into account. Heterogeneity between relative risk
estimates was assessed using chi-squared statistics.
To ensure that women in one study were compared directly
only with similar women in the same study, all analyses were
routinely stratified by study, by centre within study, by age (in 5-y
age groups, with women aged over 90 y excluded), parity (0, 1+),
use of oral contraceptives (no, for ,5 y, 5+ y), ever use of
hormonal therapy for the menopause (yes, no), and menopausal
status or hysterectomy (pre/perimenopausal, natural menopause
before age 50, natural menopause after age 50, previous
hysterectomy, other). Unknowns for each stratification variable
were assigned to separate strata. Analyses in relation to height
were also adjusted by body mass index, and analyses in relation to
body mass index and to weight were also adjusted by height;
results of sensitivity analyses to assess the effect of these mutual
adjustments are presented. The effect on the main findings of
other potential confounding factors (year of birth, ethnic group,
education, family history of ovarian or breast cancer, age at
menarche, menopausal status, alcohol use, and smoking) was
examined by comparing results before and after stratification for
each variable, in turn, and all simultaneously.
The relative risk of ovarian cancer per 5 cm increase in height
and per 5 kg/m2 increase in body mass index was estimated by
fitting a log-linear trend across categories of height (,155, 155–,
160–, 165–, 170–, 175+ cm) and body mass index (,20, 20–,
22.5–, 25–, 27.5–, 30–, 32.5–, 35+ kg/m2) using the median value
within each category.
Results in the figures are presented by squares and lines,
respectively, representing the relative risks and their corresponding
95% or 99% CIs or g-s CIs. The position of the square indicates
the value of the relative risk, and its area is inversely proportional
to the variance of the logarithm of the relative risk, thereby
providing an indication of the amount of statistical information
available for that particular estimate. When results from many
studies or many subgroups are presented in the figures, 99% CIs/
g-s CIs are given, since because of the multiple testing, p-values
greater than 0.01 may well be due to chance. In the text and in
figures summarizing the main results, 95% CIs are given.
In high-income countries the average height has increased by
about 1 cm per decade [58], and the average body mass index has
increased by about 1 unit per decade [59]. To illustrate the public
health consequences of the secular trend of increasing height and
weight among women in such countries, we applied the relative
risks obtained here per centimetre increase in height and per unit
increase in body mass index to estimate how ovarian cancer rates
would have changed per decade, had all other factors relevant for
ovarian cancer remained constant. The PRISMA checklist is
provided as Text S1.
Results
Details of the women in the 47 participating studies are shown
in Table 1. The studies are grouped by their design and, within
each type of design, are ordered by the median year when the
ovarian cancers were diagnosed. Altogether the 47 studies were
conducted in 14 countries. The studies contributed a total of
25,157 women with ovarian cancer (cases) and 81,311 women
without ovarian cancer (controls), with almost half the cases from
Europe and half from North America. The cancers were
diagnosed in 1994, on average, and the mean age at diagnosis
was 57.6 (standard deviation, 12.5) y. The percentages aged ,35,
35–44, 45–54, 55–64, and 65 y or older at diagnosis were 5%,
10%, 22%, 32%, and 31%, respectively. Among controls the
average height was 162.7 (standard deviation, 7.0) cm, and the
average body mass index was 25.0 (standard deviation, 4.9) kg/m2.
Ovarian cancer risk increased significantly both with increasing
height and with increasing body mass index (p,0.001 for each).
However, there was highly significant variation in the findings by
study design (pheterogeneity,0.001 for each); this is illustrated in
Figure 1, which shows study-specific relative risks of ovarian
cancer risk per 5 cm increase in height and per 5 kg/m2 increase
in body mass index, grouped by study design. Studies contributing
relatively small amounts of statistical information (where the
reciprocal of var[log relative risk] is less than 30) are included in
the ‘‘other’’ category for the relevant study design. The variation
by study design is largely due to the qualitatively different results
for case–control studies with hospital controls compared to results
for case–control studies with population controls or for prospective
studies. The possibility that some of the hospital controls were
women with conditions affected by height and body mass index
cannot be excluded, and so studies with hospital controls are











Mean Height (cm)/Mean Body
Mass Index (kg/m2) (Controls)
PEDS (US) [20] 411/1,752 1989 1933 54.5 162.5/25.5
Tzonou/Tricopoulos (Greece) [6] 319/396 1990 1929 56.0 160.9/24.7
Negri (Italy) [19] 1026/2,398 1995 1939 54.9 161.1/25.3
Zhejiang-Curtin (China) [34] 287/652 1999 1952 46.3 158.3/22.1
All with hospital controls 5,328/15,360 1986 1932 52.7
All 47 studies 25,157/81,311 1994 1935 57.6 162.7/25.0
NA, not available.
doi:10.1371/journal.pmed.1001200.t001
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Height
The taller women were, the greater was their risk of ovarian
cancer (Table 2). The adjusted relative risk for ovarian cancer was
1.07 (95% CI, 1.05–1.09, p,0.001) for every 5 cm increase in
height. Analyses were stratified by study, age, parity, menopausal
status, hysterectomy, oral contraceptive use, use of hormone
therapy for the menopause, and body mass index. It can be seen in
Table 2 that, without stratification for body mass index, the
relative risk estimates associated with increasing height were very
slightly lower, by less than 1%, than they were with such
stratification. We also assessed the effect of further adjustment for
seven other potential confounding factors: ethnic group, educa-
tion, age at first birth, family history of ovarian or breast cancer,
age at menarche, alcohol use, and tobacco consumption. The
estimates of relative risk were altered by less than 1% by additional
adjustment for individual factors, and simultaneous adjustment for
all seven factors did not alter the estimate.
The magnitude of the increase in the relative risk of ovarian
cancer with increasing height did not vary substantially by age,
year of birth, education, age at menarche, parity, use of oral
contraceptives, menopausal status, use of menopausal hormone
therapy, hysterectomy, smoking, alcohol consumption, or
having first degree relatives with breast or ovarian cancer
(Figure 2). The trend appeared to be somewhat greater in non-
white than in white women, but the difference was of borderline
significance (pheterogeneity = 0.02), and, given the large number of
comparisons made, it may well be due to chance. There was no
significant heterogeneity in the relationship between height and
ovarian cancer risk between prospective studies and case–
control studies with population controls (Figure 1; pheterogeneity =
0.07). Since the associations did not vary materially across the
various subgroups studied and additional adjustment for other
potential confounders had little effect, the overall relationship
between height and the relative risk of ovarian cancer can be
summarized as shown in Figure 3, where the relative risks in
each category of height are plotted against the mean height in
that category.
Weight and Body Mass Index
The heavier and the more obese women were, the greater was
their risk of ovarian cancer (Table 2). These results were obtained
after all data were stratified by age, study, parity, menopausal
status, hysterectomy, oral contraceptive use, use of hormone
therapy for the menopause, and height. As expected, adjustment
for height reduced the relative risks of ovarian cancer associated
with increasing weight but had little effect on the relative risks
associated with increasing body mass index (Table 2). Since the
association between weight and ovarian cancer risk is dependent
on height, but the association with body mass index is not,
subsequent analyses focus on body mass index.
The magnitude of the increase in the relative risk of ovarian
cancer with increasing body mass index did not vary significantly
by women’s age, year of birth, ethnic group, education, age at
menarche, parity, use of oral contraceptives, menopausal status,
Figure 1. Relative risk of ovarian cancer in relation to height and body mass index by study. Relative risk1 (RR1) is stratified by study, age
at diagnosis, parity, menopausal status/hysterectomy, body mass index, duration of oral contraceptive use, and ever use of hormone therapy. Relative
risk2 (RR2) is stratified by study, age at diagnosis, parity, menopausal status/hysterectomy, height, duration of oral contraceptive use, and ever use of
hormone therapy. SE, standard error.
doi:10.1371/journal.pmed.1001200.g001
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hysterectomy, alcohol and tobacco use, or family history of breast
or ovarian cancer (Figure 2). However, use of hormone therapy for
the menopause had a substantial effect on the association
(pheterogeneity,0.001). The relative risk of ovarian cancer increased
with increasing body mass index among never-users of meno-
pausal hormone therapy, but not among ever-users (relative risk
per 5 kg/m2 increase in body mass index of 1.10 [95% CI, 1.07–
1.13], p,0.001; and 0.95 [95% CI, 0.92–0.99], p = 0.02,
respectively). Given that almost 60 subgroup-specific relative risks
are shown in Figure 2, the p-value of 0.02 for users of hormone
therapy is of borderline significance, whereas the p-values of
,0.001 for the trend in non-users and for the difference in the
trends between hormone users and non-users is unlikely to be due
to chance. Such differences were observed both in prospective
studies (1.08 [95% CI, 1.04–1.12] versus 0.94 [95% CI, 0.90–
0.99]; pheterogeneity,0.001) and in case–control studies with
population controls (1.13 [95% CI, 1.08–1.18] versus 0.99 [95%
CI, 0.91–1.08]; pheterogeneity = 0.008) and did not differ when
analyses were restricted to postmenopausal women.
Results in prospective studies were not significantly different
when the first 4 y of follow-up were excluded. The risk estimates
associated with body mass index in ever-users and never-users of
hormone therapy changed by less than 2% after further
adjustment for seven other potential confounding factors: ethnic
group, education, age at first birth, family history of ovarian or
breast cancer, age at menarche, and alcohol and tobacco
consumption, and simultaneous adjustment for all these factors
also affected the relative risk estimate by less than 2%. Since
factors other than hormone use did not have a major effect on the
relationship between ovarian cancer and body mass index, the
main results are summarized in Figure 4 separately for never-users
and ever-users of menopausal hormone therapy. The category-
specific relative risks for ovarian cancer are plotted against the
mean body mass index in each category.
Tumour Histology
Data on tumour histology was available for 17,039 (68%)
women with ovarian cancer included in the main analyses. The
effects of increasing height and increasing body mass index did not
differ significantly between epithelial and non-epithelial tumours
or between clear cell, endometrioid, mucinous, or serous histology
(Figure 5). However, when the data for mucinous and serous
tumours were subdivided into whether they were of only
borderline malignancy or were fully malignant, the trend with
increasing body mass index was considerably greater for
borderline serous tumours than for fully malignant serous tumours
(pheterogeneity,0.001). Borderline malignant serous tumours make
up about 5% of all the ovarian tumours included here. There were
too few borderline malignant endometrioid tumours to examine
separately. When analyses were restricted to never-users of
menopausal hormone therapy, the associations with body mass
index shown in Figure 5 did not change materially. The stronger
association with borderline than with fully malignant serous
tumours remained (relative risks per 5 kg/m2 increase in body
mass index of 1.33 [95% CI, 1.20–1.47] and 1.04 [95% CI ,1.00–
1,09], respectively, pheterogeneity,0.001); for the other tumour types
the corresponding relative risks among never-users of hormone
therapy were 1.05 (95% CI, 0.93–1.17) for clear cell, 1.10 (95%
CI, 1.02–1.19) for endometrioid, and 1.14 (95% CI, 1.06–1.22) for
mucinous tumours.
Public Health Implications
Based on the findings here, a 1 cm increase in height is
associated with a relative risk of ovarian cancer of 1.014, and a
1 kg/m2 increase in body mass index with a relative risk of 1.019,
in never-users of hormone therapy. In high-income countries,
where average height has increased by about 1 cm per decade [58]
and average body mass index by about 1 kg/m2 per decade [59],
the associated increase in ovarian cancer incidence would be 3%
Table 2. Relative risk of ovarian cancer in relation to height, weight, and body mass index.
Factor Cases/Controls Relative Riska (99% g-s CI) Relative Riskb (99% g-s CI)
Height (cm) (mean)
,160 (154.8) 5,221/18,334 1.00 (0.95–1.05) 1.00 (0.95–1.05)
160– (161.7) 5,678/19,231 1.09 (1.05–1.14) 1.10 (1.05–1.16)
165– (166.5) 4,961/16,498 1.14 (1.09–1.20) 1.15 (1.10–1.21)
170+ (172.7) 3,587/11,059 1.24 (1.17–1.32) 1.27 (1.20–1.35)
Weight (kg) (mean)
,60 (54.1) 5,870/19,904 1.00 (0.96–1.05) 1.00 (0.95–1.05)
60–69 (64.2) 6,379/22,197 1.04 (1.00–1.08) 1.02 (0.97–1.06)
70–79 (73.7) 3,939/13,183 1.11 (1.05–1.17) 1.07 (1.02–1.14)
80+ (90.3) 3,114/9,128 1.24 (1.17–1.32) 1.18 (1.10–1.26)
Body mass index (kg/m2) (mean)
,22.5 (20.6) 6,299/21,009 1.00 (0.96–1.05) 1.00 (0.95–1.05)
22.5– (23.5) 4,024/13,554 1.04 (0.99–1.10) 1.05 (1.00–1.11)
25– (25.9) 4,351/14,790 1.07 (1.02–1.12) 1.08 (1.02–1.13)
27.5– (28.4) 1,771/5,892 1.07 (0.99–1.16) 1.07 (0.99–1.17)
30+ (33.6) 3,043/9,435 1.12 (1.05–1.19) 1.13 (1.06–1.20)
Test for trend: height, p,0.001; weight, p,0.001; body mass index, p,0.001. Studies with hospital controls are excluded.
aRelative risk stratified by study, age at diagnosis, parity, menopausal status/hysterectomy, duration of oral contraceptive use, and ever use of menopausal hormone
therapy.
bRelative risk stratified as for the previous column, with additional stratification by body mass index (for height) and by height (for weight and body mass index).
doi:10.1371/journal.pmed.1001200.t002
Ovarian Cancer and Body Size
PLoS Medicine | www.plosmedicine.org 6 April 2012 | Volume 9 | Issue 4 | e1001200
(1.01961.014 = 1.03) per decade in never-users of hormone
therapy, if all other factors relevant for the disease remained
constant.
Discussion
Our collaboration has brought together and re-analysed
individual data from 47 studies on ovarian cancer risk associated
with adult height, weight, and body mass index, that is, most of the
available epidemiological information worldwide. Collectively, the
findings show a highly significant increase in the risk of ovarian
cancer with increasing values for each of the anthropometric
variables examined. The increase in ovarian cancer risk with
increasing height and with increasing body mass index did not
vary materially by women’s age, year of birth, ethnicity, education,
age at menarche, parity, family history of ovarian or breast cancer,
use of oral contraceptives, menopausal status, hysterectomy, or
consumption of alcohol and tobacco. However use of hormone
therapy for the menopause attenuated the relationship with body
mass index, since an increase in ovarian cancer risk with increasing
adiposity was found only in never-users of such therapy. The
trends with increasing height and body mass index were broadly
similar across the common histological subtypes of ovarian cancer,
except for serous tumours of borderline malignancy, which
comprise 5% of the total, where the increase in risk with
increasing body mass index was considerably greater than for
the other tumour subtypes.
An advantage of seeking to review all epidemiological studies of
ovarian cancer with relevant information on body size, published
and unpublished, is that this helps avoid unduly selective emphasis
on published results or just on some studies. Three eligible studies
that did not contribute data to these analyses but that had
published on ovarian cancer risk associated with height and/or
body mass index, [48–51], and some small cohorts that
contributed to a fourth study [52], together contain less than
10% as many women with ovarian cancer as are included here,
and as their findings do not differ materially from those reported
here, failure to include them will not have materially altered the
relationships reported here. Only about half the eligible studies
had published on body size and ovarian cancer risk. Few of these
studies published separate results by use of hormone therapy, and
so reviews based solely on published findings on the relation
between body mass index and ovarian cancer risk could be
misleading. The total number of studies that did not meet the
eligibility criteria for this collaboration is unknown, as details of
such studies have not been routinely collected over the 15 y since
Figure 2. Relative risk of ovarian cancer in relation to height and BMI in various subgroups of women. Relative risk1 (RR1) is stratified by
study, age at diagnosis, parity, menopausal status/hysterectomy, body mass index, duration of oral contraceptive use, and ever use of hormone
therapy (HT). Relative risk2 (RR2) is stratified by study, age at diagnosis, parity, menopausal status/hysterectomy, height, duration of oral contraceptive
use, and ever use of hormone therapy. { numbers do not always add to the total because of missing values; { never-user of hormone therapy. Case–
control studies with hospital controls are excluded. The dotted line represents the overall result for all women. SE, standard error.
doi:10.1371/journal.pmed.1001200.g002
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the collaboration began. Furthermore, despite extensive efforts to
identify all eligible studies with unpublished results, it is clearly
impossible to guarantee that others do not exist. It is also not
possible to have completely up-to-date information from continu-
ing prospective studies that are accumulating data beyond the time
when information was contributed to this collaboration. Unpub-
lished results from known continuing prospective studies may
contain at least another 5% as many women with ovarian cancer
as are included here, but there is no good reason to expect that
over the next few years inclusion of additional data from such
studies will materially alter the evidence that is already available.
Results from case–control studies that used hospital controls
differ qualitatively and significantly from those with other study
designs. It seems unlikely that these differences are due to the
retrospective reporting of height and/or weight, since the results
differ substantially between the retrospective studies that used
hospital controls and the retrospective studies that used population
controls. While other factors might also be relevant, many of the
retrospective studies with hospital controls were designed to
examine the effects of hormonal factors on ovarian cancer risk,
and controls were often recruited from orthopaedic wards, where
the most common reason for admission among middle-aged
women is for hip and knee replacement surgery, and the risk of
these conditions increases markedly with increasing height and
increasing body mass index [60]. Using such controls to study the
role of anthropometric factors in ovarian cancer would dilute, and
could even reverse, any association. Since insufficient information
was provided centrally on diagnoses among controls, the possibility
of such biases could not be excluded, and studies with hospital
controls were omitted from the main analyses. Nevertheless, to
ensure that the totality of the epidemiological information is
published, details of those studies are given in Table 1 and in
Figure 1.
In prospective studies, height and weight were generally
recorded at the time that women were recruited into the cohort,
and in case–control studies, women were generally asked about
their height and weight some 1–5 y before the diagnosis of ovarian
cancer (for cases) and at an equivalent time for controls. In the
case–control studies with population controls, the retrospective
reporting of height and weight may have been influenced by the
cases’ knowledge that they had ovarian cancer, but the similarity
of the findings in such studies and in those with prospective
recording of anthropometric factors suggests that this is probably
not a serious problem here. Nonetheless, there is still likely to be
some measurement error, not only in retrospective self-reported
data but also with measurements made at entry into a prospective
study, because women’s weight (and, to a lesser extent, their
height) may change over time. Non-differential misclassification of
Figure 3. Relative risk of ovarian cancer by height. Relative risk
compared to women with height ,160 cm and stratified by study, age
at diagnosis, parity, menopausal status/hysterectomy, body mass index,
duration of oral contraceptive use, and ever use of hormone therapy.
Relative risk estimates are plotted against the mean height in each
category (,160, 160–164, 165–169, and 170+ cm). Case–control studies
with hospital controls are excluded.
doi:10.1371/journal.pmed.1001200.g003
Figure 4. Relative risk of ovarian cancer by body mass index.
Relative risk in (A) never-users of hormone therapy (HT) and (B) ever-
users of hormone therapy, taking women with a body mass index of
,25 kg/m2 in each group as the baseline (relative risk = 1.0), and
stratified by study, age at diagnosis, parity, height, and duration of oral
contraceptive use. Results for never-users of hormone therapy are
additionally stratified by menopausal status/hysterectomy, and results
for ever-users of hormone therapy are restricted to postmenopausal
women. Relative risk estimates are plotted against the mean body mass
index in each category (,25, 25–29, and 30+ kg/m2). Case–control
studies with hospital controls are excluded.
doi:10.1371/journal.pmed.1001200.g004
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these variables would dilute estimates of relative risk, although the
effects are likely to be comparatively small [61].
The observed association between ovarian cancer and height
did not differ significantly between prospective studies and
retrospective studies with population controls, nor did it vary by
the 12 personal characteristics of the women that were examined
(Figure 2). Variation in height reflects genetic and environmental
influences, acting mostly in the first 20 or so years of life, with the
role of environmental factors, including childhood nutrition and
infections, believed to predominate [62]. The observed relation-
ship may reflect the biological influence of factors associated with
adult height that are not yet well characterized or understood,
such as the number of cells at risk of developing into cancer [63] or
variation in levels of circulating growth factors, such as insulin-like
growth factor-1 [64].
The association between ovarian cancer and body mass index is
seen across all subgroups of women studied, except ever-users of
menopausal hormone therapy. The relevance of the finding in
users of menopausal hormones will be examined in a future report
from this collaboration, where the direct relationship between
ovarian cancer risk and use of menopausal hormone therapy will
be examined, and the potential modification of any effect of
hormone therapy by women’s adiposity and other factors will be
explored. Body mass index is in general a good measure of
adiposity, although women with the same value for the index may
vary in the relative contribution from fat and from muscle. The
finding that use of hormone therapy largely eliminates the
relationship between body mass index and ovarian cancer risk
suggests that endogenous oestrogens may be relevant, at least
among postmenopausal women: the well-characterized association
between circulating oestrogen levels and increasing adiposity in
postmenopausal women who do not use hormonal therapies is
likely to be altered among users of these therapies [65]. It is
unknown why the association with body mass index was greater
for borderline malignant serous tumours than for other ovarian
tumour types. Borderline malignant serous tumours appear to
differ from fully malignant serous tumours in certain mitochon-
drial DNA sequences, but the relevance of these genetic
differences to the observed associations with adiposity is unclear
[66].
Among women in high-income countries, average height has
increased by about 1 cm per decade and average body mass index
has increased by about 1 kg/m2 per decade in the generations of
women now developing ovarian cancer [58,59]. As an illustration
of the public health consequences of such changes in height and
weight, these findings suggest an associated increase in ovarian
cancer incidence of 3% per decade if all other factors relevant for
ovarian cancer remained constant.
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Editors’ Summary
Background. Cancer of the ovaries, usually referred to as
ovarian cancer, is the fifth leading cause of cancer death in
women, and, unfortunately, symptoms (such as abdominal
pain and swelling) usually occur late in the disease process;
fewer than one-third of ovarian cancers are detected before
they have spread outside of the ovaries. There is no
definitive evidence that screening reduces mortality from
ovarian cancer, and given the poor prognosis of advanced
ovarian cancer, there has been much research over recent
years to increase understanding of this serious condition.
There are recognized risk factors that increase the chance of
developing ovarian cancer, such as increasing age, having
fewer children, not having used oral contraceptives, and use
of menopausal hormone therapy. Age and oral contraceptive
use have by far the biggest impact on ovarian cancer risk.
Why Was This Study Done? To date, there is no definitive
information about the relevance of women’s height, weight,
and body mass index to their subsequent risk of developing
ovarian cancer. There have been roughly 50 epidemiological
studies of ovarian cancer, but only about half of these
studies have published results on the association between
body size and ovarian cancer risk, and so far, these findings
have been inconsistent. Therefore, the researchers—an
international collaboration of researchers studying ovarian
cancer—re-analyzed the available epidemiological evidence
to investigate the relationship between ovarian cancer risk
and adult height, weight, and body mass index, and to
examine the consistency of the findings across study
designs.
What Did the Researchers Do and Find? After an
extensive literature search, the researchers identified 47
eligible studies that collected individual data on women’s
reproductive history, use of hormonal therapies, height,
weight, and/or body mass index, and in which the principal
investigators of each study accepted the invitation from the
researchers to be involved in the re-analysis. The researchers
combined data from the different studies. To ensure that
women in one study were only directly compared with
controls (similar women without ovarian cancer) in the same
study, all analyses were routinely stratified by study, center
within study, age, parity, use of oral contraceptives, use of
hormonal therapy for menopause, and menopausal status or
hysterectomy.
The 47 studies were conducted in 14 countries and
comprised a total of 25,157 women with ovarian cancer
(mostly from Europe and North America) and 81,311 women
without ovarian cancer. The researchers found a significant
increase in relative risk (1.07) of ovarian cancer per 5 cm
increase in height. Furthermore, this risk did not vary
depending on other studied factors—age, year of birth,
education, age at menarche, parity, menopausal status,
smoking, alcohol consumption, having had a hysterectomy,
having first degree relatives with ovarian or breast cancer,
use of oral contraceptives, or use of menopausal hormone
therapy. However, the researchers found that for body mass
index, the risks depended on whether women had ever
taken menopausal hormone therapy: the relative risk for
ovarian cancer per 5 kg/m2 increase in body mass index was
1.10 in women who had never taken menopausal hormone
therapy but was only 0.95 in women who had previously
taken menopausal hormone therapy.
What Do These Findings Mean? These findings suggest
that increasing height can be considered as a risk factor for
ovarian cancer and that in women who have never taken
menopausal hormone therapy, increased body mass index
can be considered an additional risk factor. These findings
have public health implications, especially in high-income
countries, because the average height of women has
increased by about 1 cm per decade and average body
mass index has increased by about 1 kg/m2 per decade. The
findings suggest an associated increase in ovarian cancer
incidence of 3% per decade if all other factors relevant for
ovarian cancer remain constant.
Additional Information. Please access these web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001200.
N The following organizations give more information on
ovarian cancer which may be of use to patients:
MedicineNet, the US National Cancer Institute, Ovarian
Cancer National Alliance, Macmillan Cancer Support
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